Regency Capital Management Inc. DE Has $4.17 Million Holdings in Aura Biosciences, Inc. $AURA

Key Points

• Regency Capital Management Inc. DE has reduced its stake in Aura Biosciences by 11.2%, now holding 665,881 shares valued at approximately $4.17 million, constituting 2.2% of its total portfolio.
• The stock of Aura Biosciences has seen a 2.1% decline recently, with current trading at around $5.92, down from a 12-month high of $12.38.
• Aura Biosciences has received mixed ratings from analysts, with a consensus rating of "Moderate Buy" and an average price target of $22.00.

Regency Capital Management Inc. DE decreased its position in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 11.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 665,881 shares of the company's stock after selling 83,601 shares during the period. Aura Biosciences makes up 2.2% of Regency Capital Management Inc. DE's holdings, making the stock its 18th biggest holding. Regency Capital Management Inc. DE owned about 1.32% of Aura Biosciences worth $4,168,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in shares of Aura Biosciences by 5,766.9% in the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock valued at $57,000 after purchasing an additional 9,573 shares during the period. Ascent Group LLC acquired a new stake in Aura Biosciences during the first quarter worth approximately $124,000. Dynamic Technology Lab Private Ltd bought a new stake in Aura Biosciences in the first quarter worth approximately $137,000. Harbor Capital Advisors Inc. acquired a new position in Aura Biosciences in the first quarter valued at approximately $151,000. Finally, Bank of America Corp DE boosted its holdings in shares of Aura Biosciences by 20.5% during the 4th quarter. Bank of America Corp DE now owns 51,286 shares of the company's stock worth $422,000 after buying an additional 8,709 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Aura Biosciences

In related news, SVP Amy Elazzouzi sold 7,722 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $6.70, for a total value of $51,737.40. Following the sale, the senior vice president owned 86,558 shares in the company, valued at $579,938.60. This represents a 8.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 6.30% of the stock is owned by corporate insiders.

Aura Biosciences Stock Down 2.1%

Shares of AURA opened at $5.92 on Tuesday. The business's fifty day moving average is $6.43 and its 200 day moving average is $6.18. Aura Biosciences, Inc. has a 12-month low of $4.34 and a 12-month high of $12.38. The stock has a market cap of $367.75 million, a P/E ratio of -3.02 and a beta of 0.45.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. On average, analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on AURA shares. Zacks Research upgraded shares of Aura Biosciences from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. HC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Aura Biosciences in a report on Wednesday, August 13th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aura Biosciences in a research note on Saturday, September 27th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Aura Biosciences presently has a consensus rating of "Moderate Buy" and an average price target of $22.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.